Novel marginal zone lymphoma models of resistance to the dual inhibition of PI3K and BCL2

被引：0
|
作者：
Arribas, Alberto J.
Cascione, Luciano
Cannas, Eleonora
Bellerjeau, Helen
Fuzio, Federica
Noguera, Aleix
Rinaldi, Andrea
Esteller, Manel
Zucca, Emanuele
Alimonti, Andrea
Rossi, Davide
Stathis, Anastasios
Bertoni, Francesco
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
534
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Marginal zone lymphoma: PI3Kδ inhibition and beyond
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (SUPPL 2) : S25 - S26
  • [2] Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
    Arribas, A.
    Napoli, S.
    Cascione, L.
    Gaudio, E.
    Bordone-Pittau, R.
    Barreca, M.
    Sartori, G.
    Chiara, T.
    Spriano, F.
    Rinaldi, A.
    Stathis, A.
    Stussi, G.
    Rossi, D.
    Emanuele, Z.
    Bertoni, F.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S40 - S40
  • [3] Large pharmacological screen to improve responses to dual PI3K/BCL2 inhibition in lymphomas
    Arribas, A. J.
    Chiappa, M.
    Napoli, S.
    Cannas, E.
    Cascione, L.
    Spriano, F.
    Tarantelli, C.
    Rossi, D.
    Zucca, E.
    Alimonti, A.
    Stathis, A.
    Damia, G.
    Broggini, M.
    Bertoni, F.
    SWISS MEDICAL WEEKLY, 2022, 152 : 29S - 30S
  • [4] CAR T cells in marginal zone lymphoma (MZL) models with acquired resistance to PI3K and BTK inhibitors
    Wang, S.
    Arribas, A. J.
    Tarantelli, C.
    Pradier, A.
    Zucca, E.
    Rossi, D.
    Simonetta, F.
    Bertoni, F.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S106 - S106
  • [5] PI3K/BCL2: illusion or promise for RS?
    Frenzel, Lukas P.
    BLOOD, 2021, 137 (24) : 3319 - 3321
  • [6] Pharmacological inhibition of IRAK4 with CA-4948 is beneficial in marginal zone lymphoma models with secondary resistance to PI3K and BTK inhibitors
    Guidetti, Francesca
    Arribas, Alberto J.
    Spriano, Filippo
    Barnabei, Laura
    von Roemeling, Reinhard
    Martinez, Elizabeth
    Zucca, Emanuele
    Bertoni, Francesco
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [7] Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma
    Ye, Haige
    Huang, Shengjian
    Liu, Yang
    Chen, Zhihong
    Wang, Michael
    Jiang, Vivian Changying
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (10) : 3068 - 3073
  • [8] Simultaneous Inhibition of BCL-2 and PI3K Signaling Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
    Ye, Haige
    Huang, Shengjian
    Jung, Dayoung
    Jiang, Changying
    Nomie, Krystle
    Zhang, Liang
    Wang, Michael
    BLOOD, 2018, 132
  • [9] Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors
    Arribas, A.
    Vultaggio, S.
    Andronache, A.
    Robusto, M.
    Fancelli, D.
    Cannas, E.
    Spriano, F.
    Tarantelli, C.
    Rossi, D.
    Zucca, E.
    Stathis, A.
    Varasi, M.
    Mercurio, C.
    Bertoni, F.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S108 - S108
  • [10] Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma
    Silvennoinen, Raija
    Majumder, Muntasir Mamun
    Tamborero, David
    Anttila, Pekka
    Eldfors, Samuli
    Karjalainen, Riikka
    Kuusanmaki, Heikki
    Lievonen, Juha
    Parsons, Alun
    Suvela, Minna
    Saily, Marjaana
    Porkka, Kimmo
    Heckman, Caroline A.
    BLOOD, 2014, 124 (21)
12345